Sign Out
Celecoxib capsules 200 mg may not be suitable for all dosages recommendations and therefore, other suitable available strengths and dosage forms should be used in such cases.
Use lowest effective dose for the shortest duration consistent with treatment goals for the individual patient. These doses can be given without regard to timing of meals.
Osteoarthritis: For relief of the signs and symptoms of OA the recommended oral dose is 200 mg per day administered as a single dose.
Rheumatoid Arthritis: For relief of the signs and symptoms of RA there commended oral dose is 200 mg twice daily.
Ankylosing Spondylitis: For the management of the signs and symptoms of AS, the recommended dose of celecoxib is 200 mg daily (once per day). If no effect is observed after 6 weeks, a trial of 400 mg daily may be worthwhile. If no effect is observed after 6 weeks on 400 mg daily, a response is not likely and consideration should be given to alternate treatment options.
Management of Acute Pain and Treatment of Primary Dysmenorrhea: The recommended dose of celecoxib is 400 mg initially, followed by an additional 200 mg dose if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily as needed.
Low Back Pain (LBP): The recommended dose of celecoxib is 200 mg or 400 mg daily, administered as a 200 mg single dose, or as 100 or 200 mg twice per day. Some patients may benefit from a total daily dose of 400 mg.
Special Populations: Hepatic insufficiency: The daily recommended dose of celecoxib in patients with moderate hepatic impairment (Child-Pugh Class B) should be reduced by 50%. The use of celecoxib in patients with severe hepatic impairment is not recommended (see Precautions and Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions).
Poor Metabolizers of CYP2C9 Substrates: Patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin) should be administered celecoxib with caution. Consider starting treatment at half the lowest recommended dose in poor metabolizers (i.e. CYP2C9*3/*3). (See Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions.)
